Pfizer Says Cancer Therapy Beats Standard Therapy In Late-Stage Blood Cancer Study - Pfizer (NYSE:PFE)
Benzinga
Last updated: April 30, 2026
Pfizer announced positive top-line results from a late-stage study of its cancer treatment, ELREXFIO (elranatamab), for multiple myeloma. This aggressive blood cancer affects the bone marrow and plasma cells.
- Pfizer's ELREXFIO, a bispecific antibody, targets B-cell maturation antigen (BCMA) and plays a role in B-cell development. The study, known as Magnetism-3, focused on patients with relapsed or refractory multiple myeloma.
- The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to the standard of care. ELREXFIO showed a favorable safety profile, consistent with previous studies.
- These results position ELREXFIO as a potential new treatment option for a patient population with limited alternatives. Pfizer plans to submit these findings for regulatory review in the coming months, aiming to bring this innovative therapy to patients worldwide. The company is committed to advancing oncology research and development.
